Evaluation of tachycardia

Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016 Apr 5;67(13):e27-115.Full text  Abstract

Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017 Mar 1;19(3):465-511.Full text  Abstract

Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-156.Full text  Abstract

Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015 Jun;12(6):e41-63.Full text

Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-391.Full text  Abstract

1. Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS guideline for the management of adult patients with supraventricular tachycardia: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2016 Apr 5;67(13):e27-115.Full text  Abstract

2. Katritsis DG, Boriani G, Cosio FG, et al. European Heart Rhythm Association (EHRA) consensus document on the management of supraventricular arrhythmias, endorsed by Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), and Sociedad Latinoamericana de Estimulación Cardiaca y Electrofisiologia (SOLAECE). Europace. 2017 Mar 1;19(3):465-511.Full text  Abstract

3. Bjerregaard P. Mean 24 hour heart rate, minimal heart rate and pauses in healthy subjects 40-79 years of age. Eur Heart J. 1983 Jan;4(1):44-51. Abstract

4. Mayuga KA, Fedorowski A, Ricci F, et al. Sinus tachycardia: a multidisciplinary expert focused review. Circ Arrhythm Electrophysiol. 2022 Sep;15(9):e007960.Full text  Abstract

5. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-156.Full text  Abstract

6. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart disease and stroke statistics-2023 update: a report from the American Heart Association. Circulation. 2023 Feb 21;147(8):e93-621.Full text  Abstract

7. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study. Circulation. 2014 Feb 25;129(8):837-47.Full text  Abstract

8. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001 May 9;285(18):2370-5.Full text  Abstract

9. Murphy NF, Simpson CR, Jhund PS, et al. A national survey of the prevalence, incidence, primary care burden and treatment of atrial fibrillation in Scotland. Heart. 2007 May;93(5):606-12.Full text  Abstract

10. Martin SS, Aday AW, Almarzooq ZI, et al. 2024 heart disease and stroke statistics: a report of US and Global Data From the American Heart Association. Circulation. 2024 Feb 20;149(8):e347-913.Full text  Abstract

11. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7.Full text  Abstract

12. Krijthe BP, Kunst A, Benjamin EJ, et al. Projections on the number of individuals with atrial fibrillation in the European Union, from 2000 to 2060. Eur Heart J. 2013 Sep;34(35):2746-51.Full text  Abstract

13. Granada J, Uribe W, Chyou P, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol. 2000 Dec;36(7):2242-6. Abstract

14. Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardia. Eur Heart J. 2020 Feb 1;41(5):655-720.Full text

15. Rehorn M, Sacks NC, Emden MR, et al. Prevalence and incidence of patients with paroxysmal supraventricular tachycardia in the United States. J Cardiovasc Electrophysiol. 2021 Aug;32(8):2199-206. Abstract

16. Orejarena L, Vidaillet HJ, DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population. J Am Coll Cardiol. 1998 Jan;31(1):150-7.Full text  Abstract

17. Trohman RG. Supraventricular tachycardia: implications for the intensivist. Crit Care Med. 2000 Oct;28(10 Suppl):N129-35. Abstract

18. Brady PA, Low PA, Shen WK. Inappropriate sinus tachycardia, postural orthostatic tachycardia syndrome, and overlapping syndromes. Pacing Clin Electrophysiol. 2005 Oct;28(10):1112-21. Abstract

19. Lally J, Docherty MJ, MacCabe JH. Pharmacological interventions for clozapine-induced sinus tachycardia. Cochrane Database Syst Rev. 2016;(6):CD011566. Abstract

20. Vernino S, Bourne KM, Stiles LE, et al. Postural orthostatic tachycardia syndrome (POTS): State of the science and clinical care from a 2019 National Institutes of Health Expert Consensus Meeting - Part 1. Auton Neurosci. 2021 Nov;235:102828.Full text  Abstract

21. Sheldon RS, Grubb BP 2nd, Olshansky B, et al. 2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope. Heart Rhythm. 2015 Jun;12(6):e41-63.Full text

22. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines and the Heart Rhythm Society. Circulation. 2017 Aug 1;136(5):e25-59.Full text

23. Raj SR, Guzman JC, Harvey P, et al. Canadian Cardiovascular Society position statement on postural orthostatic tachycardia syndrome (POTS) and related disorders of chronic orthostatic intolerance. Can J Cardiol. 2020 Mar;36(3):357-72.Full text  Abstract

24. Steinbeck G, Hoffmann E. 'True' atrial tachycardia. Eur Heart J. 1998 May;19(Suppl E):E10-2,E48-9. Abstract

25. Kotadia ID, Williams SE, O'Neill M. Supraventricular tachycardia: an overview of diagnosis and management. Clin Med (Lond). 2020 Jan;20(1):43-7.Full text  Abstract

26. Gillette PC, Garson AJ, Kugler JD. Wolff-Parkinson-White syndrome in children: electrophysiologic and pharmacologic characteristics. Circulation. 1979 Dec;60(7):1487-95.Full text  Abstract

27. Veenhuyzen GD, Simpson CS, Abdollah H. Atrial fibrillation. CMAJ. 2004 Sep 28;171(7):755-60.Full text  Abstract

28. Medicines and Healthcare products Regulatory Agency. Omega-3-acid ethyl ester medicines (Omacor/Teromeg 1000mg capsules): dose-dependent increased risk of atrial fibrillation in patients with established cardiovascular diseases or cardiovascular risk factors. Jan 2024 [internet publication].Full text

29. Lombardi M, Carbone S, Del Buono MG, et al. Omega-3 fatty acids supplementation and risk of atrial fibrillation: an updated meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):e69-70.Full text

30. Gencer B, Djousse L, Al-Ramady OT, et al. Effect of long-term marine ɷ-3 fatty acids supplementation on the risk of atrial fibrillation in randomized controlled trials of cardiovascular outcomes: a systematic review and meta-analysis. Circulation. 2021 Dec 21;144(25):1981-90.Full text  Abstract

31. Shine KI, Kastor JA, Yurchak PM. Multifocal atrial tachycardia. Clinical and electrocardiographic features in 32 patients. N Engl J Med. 1968 Aug 15;279(7):344-9. Abstract

32. Iseri LT, Fairshter RD, Hardemann JL, et al. Magnesium and potassium therapy in multifocal atrial tachycardia. Am Heart J. 1985 Oct;110(4):789-94. Abstract

33. Deal BJ, Miller SM, Scagliotti D, et al. Ventricular tachycardia in a young population without overt heart disease. Circulation. 1986 Jun;73(6):1111-8.Full text  Abstract

34. Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation. 2018 Sep 25;138(13):e272-391.Full text  Abstract

35. Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 26 Aug 2022 [Epub ahead of print].Full text  Abstract

36. de Bakker JM, van Capelle FJ, Janse MJ, et al. Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease: electrophysiologic and anatomic correlation. Circulation. 11988 Mar;77(3):589-606.Full text  Abstract

37. Kouranos V, Sharma R. Cardiac sarcoidosis: state-of-the-art review. Heart. 2021 Oct;107(19):1591-9.

38. Nery PB, Mc Ardle BA, Redpath CJ, et al. Prevalence of cardiac sarcoidosis in patients presenting with monomorphic ventricular tachycardia. Pacing Clin Electrophysiol. 2014 Mar;37(3):364-74. Abstract

39. Nery PB, Beanlands RS, Nair GM, et al. Atrioventricular block as the initial manifestation of cardiac sarcoidosis in middle-aged adults. J Cardiovasc Electrophysiol. 2014 Aug;25(8):875-81. Abstract

40. Baughman RP, Teirstein AS, Judson MA, et al. Clinical characteristics of patients in a case control study of sarcoidosis. Am J Respir Crit Care Med. 2001 Nov 15;164(10 pt 1):1885-9.Full text  Abstract

41. Chow KL, O'Donnell JL, Crozier I. Prevalence, incidence and survival outcomes of cardiac sarcoidosis in the South Island, New Zealand. Int J Cardiol. 2022 Jun 15;357:128-33. Abstract

42. Maizels L, Mansour M, Abu-Much A, et al. Prevalence of cardiac sarcoidosis in middle-aged adults diagnosed with high-grade atrioventricular block. Am J Med. 2024 Apr;137(4):358-65. Abstract

43. Passman R, Kadish A. Polymorphic ventricular tachycardia, long Q-T syndrome, and torsades de pointes. Med Clin North Am. 2001 Mar;85(2):321-41. Abstract

44. The Cardiac Society of Australia and New Zealand. Guidelines for the diagnosis and management of catecholaminergic polymorphic ventricular tachycardia. Nov 2016 [internet publication].Full text

45. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020 Oct 13;142(15):e214-33.Full text  Abstract

46. Goldberger JJ, Cain ME, Hohnloser SH, et al. American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society scientific statement on noninvasive risk stratification techniques for identifying patients at risk for sudden cardiac death: a scientific statement from the American Heart Association Council on Clinical Cardiology Committee on Electrocardiography and Arrhythmias and Council on Epidemiology and Prevention. Circulation. 2008 Sep 30;118(14):1497-518.Full text  Abstract

47. Winkle RA, Mead RH, Ruder MA, et al. Effect of duration of ventricular fibrillation on defibrillation efficacy in humans. Circulation. 1990 May;81(5):1477-81.Full text  Abstract

48. De Maio VJ, Stiell IG, Wells GA, et al. Optimal defibrillation response intervals for maximum out-of-hospital cardiac arrest survival rates. Ann Emerg Med. 2003 Aug;42(2):242-50. Abstract

49. Rea TD, Eisenberg MS, Becker LJ, et al. Temporal trends in sudden cardiac arrest: a 25-year emergency medical services perspective. Circulation. 2003 Jun 10;107(22):2780-5.Full text  Abstract

50. Seidl K, Rameken M, Breunung S, et al. Diagnostic assessment of recurrent unexplained syncope with a new subcutaneously implantable loop recorder. Reveal-Investigators. Europace. 2000 Jul;2(3):256-62.Full text  Abstract

51. Goldberger ZD, Rho RW, Page RL. Approach to the diagnosis and initial management of the stable adult patient with a wide complex tachycardia. Am J Cardiol. 2008 May 15;101(10):1456-66. Abstract

52. Brignole M, Sutton R, Menozzi C, et al. Early application of an implantable loop recorder allows effective specific therapy in patients with recurrent suspected neurally mediated syncope. Eur Heart J. 2006 May;27(9):1085-92.Full text  Abstract

53. Krahn AD, Klein GJ, Yee R, et al. The high cost of syncope: cost implications of a new insertable loop recorder in the investigation of recurrent syncope. Am Heart J. 1999 May;137(5):870-7. Abstract

54. Svennberg E, Tjong F, Goette A, et al. How to use digital devices to detect and manage arrhythmias: an EHRA practical guide. Europace. 2022 Jul 15;24(6):979-1005.Full text

55. Bouzid Z, Al-Zaiti SS, Bond R, et al. Remote and wearable ECG devices with diagnostic abilities in adults: a state-of-the-science scoping review. Heart Rhythm. 2022 Jul;19(7):1192-201.Full text  Abstract

56. Tooley JE, Perez MV. Role of digital health in detection and management of atrial fibrillation. Heart. 2022 May 12;108(11):834-9. Abstract

57. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. Jun 2021 [internet publication].Full text